Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
KPTI
KPTI
Nasdaq
Health Technology
Pharmaceuticals: Major
6.98
USD
-0.2
-2.79%
Öffnen: 07-23 14:40 (UTC+0)

KPTI Wichtige Statistiken

Hoch
7.16
Öffnen
7.14
Volumen
147.68K
Niedrig
6.88
Vorheriger Schlusskurs
7.18
Handelswert
1.03M
52W-Hoch
10.99
Rel. Volumen
0.226
Amplitude (%)
3.83%
52W-Tief
3.65
Umsatzrate
0.65%
Marktkapitalisierung
162.71M
KGV (TTM)
--
KGV (Jährlich)
--
KBV
-0.61
KUV
1.08
Gewinn je Aktie (EPS)
-15.087
Dividende (TTM)
0
Dividendenrendite
0.00%
Ausstehende Aktien
22.66M
Währung
USD

KPTI Preis-Performance

7 Tag
30 Tag
90 Tag
180 Tag
Seit Jahresbeginn
1 Jahr
KPTI Moneyflow-Verteilung
KPTI Tägliches Leerverkaufsvolumen
KPTI Short-Interest-Historie
As of 2026-07-23, the Karyopharm Therapeutics Inc. (KPTI) stock price today is 6.98. Based on this price, the company has a market capitalization of $162.71M, with a P/E ratio of --. On 2026-07-23, KPTI traded between 6.88 and 7.16. Today’s stock price is 1.45% above the daily low and 2.51% below the daily high, placing KPTI im unteren Bereich von its most recent trading range. Trading volume currently stands at 147.68K, compared with an average daily volume of 652.72K. This suggests that trading activity is deutlich unter dem üblichen Niveau than usual. Over the past year, Karyopharm Therapeutics Inc. shares have traded between 3.65 and 10.99. At today’s price, KPTI is 91.23% above its 52-week low and 36.49% below its 52-week high.
Firmenname
Karyopharm Therapeutics Inc.
Sektor
Health Technology
Branche
Pharmaceuticals: Major
Börsen
Nasdaq
Anzahl der Beschäftigten
228
Losgröße
100
Offizielle Website
Währung
USD
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

KPTI FAQ